When are medical apps medical? Off-label use and the Food and Drug Administration

被引:3
|
作者
Krieger, William H. [1 ]
机构
[1] Univ Rhode Isl, Kingston, RI 02881 USA
来源
DIGITAL HEALTH | 2016年 / 2卷
关键词
Medical apps; Food and Drug Administration; mobile healthcare; off-label; conflict of interest;
D O I
10.1177/2055207616662782
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or 'apps' on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing mobile healthcare sector, the Food and Drug Administration has put forth guidelines to regulate 'mobile medical apps' (MMAs), those health-related apps that are (self) designated as medical devices. In this article, I argue that this decision, to only regulate apps that bill themselves as medical devices, will create a market for 'off-label' app use. Further, I will talk about the oft used analogy between off-label apps and off-label pharmaceuticals, showing that off-labeling apps will provide patients none of the benefits that come with a physician prescribing a drug off-label, while exposing the mobile healthcare consumer to significant risks that go significantly beyond those that we know of (and must accept) from prescription drugs. Recognizing that the Food and Drug Administration is not going to be able to significantly change its policies on oversight, I will suggest specific actions to at least mitigate some of the risks associated with off-label app use.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] ‘Off-label’ drug use: an FDA regulatory term, not a negative implication of its medical use
    W A Meadows
    B D Hollowell
    International Journal of Impotence Research, 2008, 20 : 135 - 144
  • [2] 'Off-label' drug use: an FDA regulatory term, not a negative implication of its medical use
    Meadows, W. A.
    Hollowell, B. D.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2008, 20 (02) : 135 - 144
  • [3] United States medical practice summary - Innovative off-label medication use
    Ansani, Nicole
    Branch, Robert
    Fedutes-Henderson, Bethany
    Smitherman, Thomas
    Weber, Robert J.
    Skledar, Susan
    Zgheib, Nathalie
    Sirio, Carl
    AMERICAN JOURNAL OF MEDICAL QUALITY, 2006, 21 (04) : 246 - 254
  • [4] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
  • [5] Off-label antidepressant prescription in pediatric outpatients based on China Food and Drug Administration and Food and Drug Administration regulations: a Chinese retrospective study
    Deng, Shuhua
    Zhu, Xiuqing
    Sun, Bin
    Hu, Jinqing
    Shang, Dewei
    Chen, Weijia
    Lu, Haoyang
    Ni, Xiaojia
    Zhang, Ming
    Wang, Zhanzhang
    Wen, Yuguan
    Qiu, Chang
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (03) : 172 - 179
  • [6] Pediatric Interventional Cardiology in the United States is Dependent on the Off-label Use of Medical Devices
    Sutherell, Jamie S.
    Hirsch, Russel
    Beekman, Robert H., III
    CONGENITAL HEART DISEASE, 2010, 5 (01) : 2 - 7
  • [7] Evaluation of medical prescriptions and off-label use on board ships to improve healthcare quality
    Nittari, G.
    Pallotta, G.
    Pirillo, I.
    Ricci, G.
    Amenta, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (13) : 4392 - 4400
  • [8] Manufacturers' promotion of off-label drug use: implications for drug safety
    Zieve, Allison
    Carome, Michael A.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (09) : 1149 - 1151
  • [9] Outcomes Associated with the Off-label Use of Medical Devices in Congenital Heart Disease at a Single Institute
    Kong, Young Hwa
    Song, Jinyoung
    Huh, Jun
    Kang, I-Seok
    KOREAN CIRCULATION JOURNAL, 2017, 47 (04) : 509 - 515
  • [10] Off-label drug use in oncology: a systematic review of literature
    Saiyed, M. M.
    Ong, P. S.
    Chew, L.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (03) : 251 - 258